Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810 PHASE1 RECRUITING

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.

Details

Lead sponsor	Mayo Clinic
Phase	PHASE1
Status	RECRUITING
Enrolment	46
Start date	Wed Aug 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Sep 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hematopoietic and Lymphatic System Neoplasm
• Histiocytic Sarcoma
• Malignant Histiocytosis
• Peripheral T-Cell Lymphoma, Not Otherwise Specified
• Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
• Recurrent Chronic Lymphocytic Leukemia
• Recurrent Chronic Myelomonocytic Leukemia
• Recurrent Follicular Lymphoma
• Recurrent Langerhans Cell Histiocytosis
• Recurrent Lymphoplasmacytic Lymphoma

Interventions

• Axl/Mer/CSF1R Inhibitor Q702
• Biospecimen Collection
• Bone Marrow Aspiration
• Bone Marrow Biopsy
• Computed Tomography
• Magnetic Resonance Imaging
• Positron Emission Tomography
• Survey Administration

Countries

United States